Out-licensing

We are eager to out-license our Nuntius biotechnology to mRNA players for the development of mRNA vaccines and therapies.

Last news

business-model

Messenger Biopharma in the newspaper “La Montagne”

posted February 15, 2016

“Messenger Biopharma in the newspaper “La ...Read More

Recent Search Keywords